Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(2S)-2-(3-bromophenyl)-3-(5-chloro-2-hydroxyphenyl)-1,3-thiazolidin-4-one is a synthetic small molecule belonging to the thiazolidinone class. It features a thiazolidine ring substituted with bromophenyl and chloro-hydroxyphenyl groups. The compound has been studied as an experimental drug candidate and is referenced in structural biology as ligand N24 or PD004617. It was used as an inhibitor in the crystallographic structure of the Bos taurus Arp2/3 complex (PDB ID: 3DXM), suggesting it may act on actin-related protein complexes[5][7][9]. However, there are no approved therapeutic indications or marketed products containing this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (2S)-2-(3-bromophenyl)-3-(5-chloro-2-hydroxyphenyl)-1,3-thiazolidin-4-one.